Denosin

Quick links to important sections

Denosin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Denosin

Quick Facts

Property Description
Active ingredient Desloratadine
Form Tablet, Oral Solution, Syrup
Pharmacological class Second-generation Antihistamine
Common use Symptomatic relief of allergic conditions
Origin Synthetic, active metabolite of Loratadine

What Type of Medicine is Denosin (Desloratadine)?

Denosin is a brand designation for a medication containing the active substance Desloratadine, which is classified pharmacologically as a highly selective peripheral H₁-receptor antagonist. This compound is categorized as a second-generation antihistamine, a designation confirming its focused action outside the central nervous system. Desloratadine is a synthetic molecule derived from the older antihistamine Loratadine, engineered to function as the primary active metabolite. Due to this origin, the compound is active upon administration without requiring further metabolic conversion.

Composition, Forms, and General Function

The Denosin formulation is a single-ingredient product featuring the API Desloratadine, presented for oral administration in preparations including tablets, oral solution, or syrup. This variety of forms, particularly the liquid option, offers a versatile preparation for diverse patient needs. The drug is clinically recognized for its anti-allergic capabilities, controlling both nasal and non-nasal symptoms. Its general function is to achieve symptomatic relief of allergic conditions by blocking the action of histamine, mitigating the chemical signals that trigger immune responses in peripheral tissues.

How is Desloratadine Unique Among Antihistamines?

Desloratadine is uniquely defined by its established profile as a non-sedating formulation, a critical differentiating factor from older antihistamine generations. This characteristic stems from its highly specific action and its minimal ability to cross the blood-brain barrier. Its high selectivity ensures therapeutic activity is concentrated on the allergic response in peripheral tissues, which is particularly beneficial for users requiring relief without the generalized depressant effects that can compromise daily cognitive function.

What side effects are possible with Denosin?

Possible Side Effects and Safety Information

The official safety profile for Denosin (desloratadine) is established through regulatory classification, detailing potential adverse reactions based on their frequency and impact on physiological systems.

Frequency-Classified Adverse Reactions

Adverse events are categorized according to their rate of occurrence observed in clinical trials and post-marketing data:

  • Common (affecting 1 to 10 users in 100): Reactions frequently listed include headache, dry mouth, and fatigue.
  • Very Rare (affecting less than 1 in 10,000 users): Reactions in this tier involve systems such as the Nervous System (e.g., somnolence, dizziness, convulsions), Cardiac System (palpitations, tachycardia), and Gastrointestinal System (nausea, abdominal pain).
  • Frequency Not Known: This category, often based on post-marketing reports, includes events like prolonged QT interval, hepatitis, jaundice, and severe hypersensitivity reactions.

Documented Serious Adverse Reactions

Regulatory documents highlight the occurrence of rare, but clinically significant, serious adverse reactions. These include severe hypersensitivity responses such as anaphylaxis and angioedema, as well as neurological events like convulsions (seizures). Specific attention is drawn to potential effects on the cardiac system, including prolonged QT interval.

Population-Specific Safety Considerations and Restrictions

The medicine is officially contraindicated in individuals with known hypersensitivity to the active substance, to any excipients, or to loratadine (the parent compound). Caution is advised for use in patients with severe renal impairment and hepatic impairment due to altered drug clearance. Furthermore, specific safety cautions are noted for the pediatric population, including the reporting of fever and diarrhea in infants, and insomnia in young children.

This structured safety information defines the official regulatory risk profile by explicitly documenting potential effects across different systems and specifying conditions where the use of the medicine is either restricted or requires particular caution.

Overdose and Emergency Response

Denosin (Adenosine) Overdose and When to Seek Help

The official regulatory profile for Denosin overdose defines its effects as a rapid, exaggerated extension of its core pharmacological action. Overdose is characterized by severe hypotension, severe bradycardia, and transient cardiac arrest (asystole). These immediate manifestations usually resolve quickly upon immediate discontinuation of administration due to the drug’s ultra-short half-life.

However, the official documents state that an overdose can lead to potentially fatal outcomes. Serious, life-threatening events documented in regulatory summaries include fatal cardiac arrest, non-fatal myocardial infarction, sustained ventricular arrhythmias, and respiratory failure or apnea.


Official Emergency and Supportive Actions

Action Area Regulatory Statement (Label-Derived)
Required Medical Help Urgent medical attention is required when severe symptoms like cardiac arrest or respiratory failure occur, as these are potentially fatal outcomes.
Monitoring and Equipment Continuous ECG monitoring and cardio-respiratory resuscitation equipment must be available for immediate use during administration.
Antagonist Methylxanthines (e.g., theophylline) are documented as competitive antagonists that may be used to terminate persistent adverse reactions.

Management primarily involves symptomatic and supportive treatment. There are no specific separate overdose notes for pediatric or elderly populations explicitly documented in the official Overdosage sections.

Therapeutic Uses of Denosin

What Denosin Treats: Main Uses and Benefits

Denosin, which contains the active substance adenosine, is generally considered relevant for acute therapeutic contexts involving symptoms related to heightened physiological activity. It plays a role in managing symptoms related to certain overly fast heart rhythms.

Intravenous adenosine is applied for managing symptoms associated with paroxysmal supraventricular tachycardia (PSVT). This means the drug is commonly used in clinical settings to help address symptoms that become more disruptive during flare-ups associated with these fast heart rhythms. The medication is relevant in conditions characterized by periods of heightened symptoms, such as those leading to temporary functional strain or discomfort.

“Applied in contexts where additional symptomatic support is needed.”

The medication is applied in addressing situations where symptoms become more noticeable and create noticeable interference with daily comfort due to the heart's rapid rate. Denosin provides support that helps ease the overall symptom burden during these episodes, contributing to improved comfort and may help patients cope more steadily with difficult episodes.

Quick Fact: Support for Overly Fast Heart Rhythms

Eligibility and Restrictions for Use

Eligibility and Contraindications for Denosin

Eligibility for Denosin (Desloratadine) is officially defined by regulatory authorities based on allergy status, age, and specific pre-existing conditions.

Contraindicated Populations

Denosin is contraindicated for any patient with a known hypersensitivity to the active substance, Desloratadine, its parent drug Loratadine, or any of the product’s excipients. Due to components in certain tablet forms, use is also prohibited for individuals with rare hereditary problems such as galactose intolerance or total lactase deficiency.

Age and Health Restrictions

Use is established for adults and adolescents 12 years of age and older. For the pediatric population, specific liquid formulations are approved for use starting at 6 months of age, but the safety of film-coated tablets is not established in children under 12 years. Caution is required for patients with severe hepatic impairment or severe renal insufficiency, or those with a medical or familial history of seizures.

Pregnancy and Lactation

During pregnancy, use is preferable to avoid as a precautionary measure. Regulatory guidance states that women must decide to discontinue breastfeeding or discontinue therapy, as Desloratadine is excreted into human milk.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Denosin (Desloratadine)


Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Antifungals, Macrolide Antibiotics, H₂-receptor Antagonists, Selective Serotonin Reuptake Inhibitors, and Ethanol (Alcohol).
Specific interacting medicines (if explicitly listed) Ketoconazole, Erythromycin, Azithromycin, Cimetidine, and Fluoxetine.
Timing-based interaction rules (if applicable) None documented. Administration is permitted with or without a meal.
Population-specific interaction notes (if applicable) Increased systemic exposure is documented in patients with severe renal impairment and hepatic impairment, as well as in individuals identified as poor metabolizers.

Interaction Classifications (High-Level)

Category Official Regulatory Statement
Interaction severity classification Non-Clinically Relevant Pharmacokinetic Interaction. Co-administration with some drugs, despite increasing plasma concentrations, resulted in no clinically relevant changes to the safety profile.
Interaction-context constraints Food does not affect the bioavailability of desloratadine. Concomitant use with alcohol was found not to potentiate its performance-impairing effects in clinical pharmacology trials.

Resulting Interaction Structure

The official interaction profile is defined by pharmacokinetic observations and their regulatory classification. Co-administration with specific medicines, including Ketoconazole and Erythromycin, results in a documented increase in systemic exposure (Cmax and AUC) of the medicine and its active metabolite. However, regulatory documents formally classify this pharmacokinetic change as not clinically relevant to the safety profile. Other substances like Azithromycin, Cimetidine, and Fluoxetine are also documented to elevate blood plasma concentrations. No formal contraindications or mandatory timing separation rules are noted within the product's official labeling. The regulatory data confirms the medicine does not potentiate the effects of alcohol on performance, and food intake does not impact absorption. Systemic exposure is further influenced by patient-specific conditions, with severe renal or hepatic impairment and the status of poor metabolizer resulting in higher overall drug exposure.

Mechanism of Action

Receptor-Mediated Signaling Modulation

Denosin exerts its action by engaging purinergic adenosine receptors (A1, A2A, etc.) found on the surface of cells, primarily within the cardiovascular system. This interaction initiates or suppresses key intracellular signaling sequences to influence the activity of these pathways.


Influencing Nodal Conduction and Hyperpolarization

The drug specifically targets the atrioventricular (AV) node, modulating conduction time by acting as an agonist at A1 receptors. This binding activates an inhibitory G-protein, which decreases calcium influx and increases potassium efflux. The resulting change in ion flux leads to hyperpolarization of the cell membrane, generating physiological adjustments of nodal conduction velocity.


Modulation of Systemic Pathway Response

Denosin also influences signaling pathways by affecting intracellular systems where secondary messengers, such as cyclic AMP, are critical. This engagement results in the inhibition of adenylyl cyclase activity, thereby modulating the magnitude of the pathway response.

Dosage and Administration Information

Official Administration Guidelines for Denosin (Desloratadine)

Denosin is designated strictly for oral administration and is available in multiple forms, including tablets, oral solution, and orally disintegrating tablets (ODT). The primary usage pattern is based on a standardized once-daily schedule (once every 24 hours), which is independent of meal timing.

Feature Official Use Principle
Standard Adult Dosing 5 mg once daily. Doses exceeding 5 mg are not proven to provide additional therapeutic benefit.
Relation to Food May be taken without regard to meals or food intake.
Usage Pattern Treatment duration is determined by the temporal nature of symptoms, allowing for intermittent use (discontinuation upon symptom resolution) or persistent use (continued administration).

Specific Administration Procedures

The specific formulation dictates the administration method. Standard tablets must be swallowed whole with fluid. The oral solution requires the use of a calibrated measuring device to ensure dosage accuracy. For the ODT form, the tablet must be allowed to disintegrate on the tongue immediately after removal from its blister packaging.

Population-Specific Dosing Rules

Specific dose modifications are indicated for certain patient groups. For adults diagnosed with either renal or hepatic impairment, the labeled regimen recommends administering the 5 mg dose every other day instead of daily. Additionally, for pediatric patients under the age of 12, lower-strength liquid or specific ODT forms are used, as the efficacy and safety of the 5 mg film-coated tablet are not established for this age bracket.

Recent Clinical Evidence

Denosin: Recent Clinical Evidence

Research has investigated the clinical profile of this compound. This non-steroidal anti-inflammatory drug (NSAID) has been the subject of multiple clinical trials. Specifically, studies have investigated its role in acute inflammatory states. Research examined pain scores following procedures like dental surgery or soft tissue injury. Research explored its association with the inflammatory response in these contexts.


Clinical Trial Data: Focus on Short-Term Use

Studies have focused on short-term investigation, typically examining outcomes over a period of 5 to 7 days. Clinical trials have assessed the compound’s observed profile and results in comparison to both placebo and other commercially available non-selective NSAIDs.

Information is available regarding outcomes related to potential risks, including gastrointestinal and cardiovascular events, which researchers assessed in the trial populations.


Comparative Studies

Research has compared outcomes associated with this compound to those associated with traditional NSAIDs across various study models.

Phase III trials reported a difference in results relative to placebo in patients with acute musculoskeletal discomfort, including the time of onset of effect and the observed adverse event profile. Further investigation has examined whether the compound and its components may affect gastrointestinal mucosa differently than non-selective NSAIDs.


Fixed-Dose Combination (FDC) Formulations

Some research has focused on formulations combining the compound with an antacid component (e.g., magnesium hydroxide). The combination was studied to see whether it altered absorption and bioavailability of the active pharmaceutical ingredient.

Research has explored whether the combination was associated with changes in comfort, and has examined the safety profile in a subset of patients. Findings were mixed, with some studies reporting no statistically significant difference in outcome compared to the compound alone, while other research examined pharmacokinetic outcomes.

Key Studies & References

  1. Multidisciplinary Guidelines for the Rational Use of Topical Non-Steroidal Anti-Inflammatory Drugs for Musculoskeletal Pain (2022)
  2. Q How do oral NSAIDs compare to other oral analgesics right after an acute musculoskeletal injury? (Cochrane review summary)

Frequently Asked Questions (FAQ)

Common questions about Denosin (FAQ)


Q: What happens if I forget to take a Denosin dose?

If a dose is missed, official patient information advises taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, regulatory guidelines recommend skipping the missed dose and resuming the regular schedule. Taking a double dose is generally advised against.


Q: Are there any long-term side effects of Denosin that are known?

Regulatory documents primarily detail adverse reactions observed during short-term clinical trials, often covering a period of 5 to 7 days, and through ongoing post-marketing surveillance. This information describes risks observed during the studies, but conclusions about the safety profile for use over many months or years are limited.


Q: Can Denosin affect my blood pressure?

Official adverse reactions lists do not explicitly state that Denosin affects blood pressure. However, regulatory documents list tachycardia (a fast heart rate) and palpitations as very rare side effects. Regulatory caution suggests that patients with pre-existing heart conditions consult a healthcare provider.


Q: Is Denosin approved for use in older adults (seniors)?

Official documents define the use of the medication in older adult populations. Studies show that drug exposure may be increased, and the drug may stay in the system longer for subjects aged 65 and older. Despite these pharmacokinetic changes, official labeling generally states that no routine dosage adjustment is required based on age alone.


Q: Is Denosin a controlled substance?

No. Official classification by U.S. regulatory authorities confirms that Denosin, which contains the active ingredient desloratadine, is not a federally controlled substance.


Q: Is Denosin known to cause weight gain or loss?

Based on regulatory review of clinical trial data, weight changes (either gain or loss) are not typically listed among the common or very rare adverse reactions associated with the use of Denosin.


Q: Does Denosin cause any unusual dreams?

Unusual dreams or nightmares are not typically listed among the Nervous System adverse reactions documented in official regulatory safety documents for Denosin. Side effects related to the nervous system are mostly categorized as very rare.


Q: Does Denosin require any special monitoring or blood tests?

For general use in healthy individuals, the regulatory label does not typically require routine special monitoring or blood tests. However, dose adjustments may be required for patients with severe kidney or liver impairment, which is determined by a healthcare provider.


Q: What happens if I accidentally take two doses of Denosin?

Studies examining the effects of taking doses higher than recommended (up to nine times the usual daily amount) showed effects like an increased heart rate. Regulatory guidance notes that contact with a healthcare provider or poison control center is advised if an overdosage is suspected.


Q: How long does Denosin stay in your system?

Official pharmacokinetic data indicates that the drug has an estimated mean plasma elimination half-life of approximately 27 hours in healthy adults. This means it takes about 27 hours for half of the drug to be cleared from the bloodstream. This half-life may be slightly longer in older adults.


Q: Is there a generic version of Denosin available?

Yes. Regulatory agencies have approved and recognized generic versions of the active ingredient desloratadine, making them available as equivalent alternatives to Denosin.


Q: Does Denosin affect fertility in men or women?

Animal studies do not suggest harmful effects on fertility at typical exposure levels. Official regulatory documents indicate that data on the effects on human fertility are limited.


Q: Can Denosin make me more sensitive to the sun?

Official safety documents do not commonly list photosensitivity (increased sensitivity to sunlight) as an expected side effect of Denosin. This reaction is generally not listed among the common or very rare adverse events.


Q: Is Denosin known by any other brand names internationally?

Yes, the active ingredient in Denosin, desloratadine, is widely available and marketed under many different brand names globally. Examples include Aerius, Clarinex, and Neoclarityn, depending on the country of use.


Q: How quickly can I expect to see an effect from Denosin?

The speed of onset is typically assessed in clinical trials. While studies have examined the time it takes for an effect to start, official documents describing this drug's use for allergy relief do not provide a precise time frame for when a patient should expect to feel the primary benefit.


Q: What kind of common over-the-counter medicines should I look out for when taking Denosin?

Official documents list certain classes of medicines that can increase the amount of Denosin in the body, such as some H2-receptor antagonists (used for stomach acid) and macrolide antibiotics. While this change is generally classified as not clinically relevant, consultation with a healthcare provider or pharmacist is advised regarding all other concurrent medications.


Q: Why does the official document warn against using Denosin with certain heart conditions?

Official documentation does not typically state a contraindication based on all heart conditions. However, the safety profile includes the potential for rare side effects like prolonged QT interval (a change in the heart's electrical rhythm). Caution is noted in regulatory documents for patients with pre-existing risk factors, which include the potential for the prolonged QT interval.


Q: Does Denosin affect my ability to operate machinery?

Denosin is classified as a non-sedating antihistamine, meaning it is not expected to cause drowsiness in most people. However, official safety profiles list very rare side effects like somnolence (drowsiness) and dizziness. Patients are generally advised to be aware of how they respond to the medication before driving or operating machinery.


Q: What is the typical experience of starting Denosin?

The typical initial experience is often uneventful, given that the drug is classified as non-sedating. However, the most commonly reported side effects when starting the medication include headache, dry mouth, and fatigue. These reactions are usually mild and manageable.


How should Denosin be stored and disposed of?

How to Store and Dispose of Denosin?

The storage and disposal instructions for Denosin (Desloratadine tablets) are based strictly on official regulatory labeling to ensure product stability and safety.

Mandatory Storage Requirements

Denosin must be stored within a controlled environment, adhering to specific temperature and protection rules:

  • Temperature: Store the product at room temperature, not exceeding 30 C (86 F).
  • Protection: Keep the tablets in the original container or packaging to protect them from moisture.
  • Child Safety: It is mandatory to store the medicine out of the sight and reach of children.

Official Disposal Rules

Unused or expired Denosin should be disposed of in a manner that follows local regulations for pharmaceutical waste. Do not discard the product via wastewater or household trash unless specifically instructed to do so by local health authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Denosin found in:

A-Z Index: